Ivonescimab: all 132 studies that test it
Page 2 of 2. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.
- Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic CancerRecruitingNCT06491472Phase 2
- A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell CarcinomaNot yet recruitingNCT06472895Phase 1/2
- A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaEnrolling by invitationNCT06424626Phase 1
- SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast CancerRecruitingNCT06402435Phase 2
- Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung CancerNot yet recruitingNCT06391008Phase 2
- AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLCNot yet recruitingNCT06196814Phase 1/2
- A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT06196775Phase 2
- AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ CancerRecruitingNCT06196697Phase 2
- Study of AK119 Combined With AK112 in Patients With Advanced Solid TumorsRecruitingNCT05689853Phase 1/2
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
- Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural MesotheliomaActive, not recruitingNCT07885306Phase 1
- A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male SubjectsActive, not recruitingNCT07340476Phase 1
- STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1WithdrawnNCT07038915Phase 2
- AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic CancerActive, not recruitingNCT06646055Phase 1/2
- AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerActive, not recruitingNCT06591520Phase 3
- A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLCCompletedNCT06478043Phase 2
- Phase III Study of AK112 for NSCLC PatientsActive, not recruitingNCT06396065Phase 3
- AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung CancerActive, not recruitingNCT05904379Phase 1/2
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsActive, not recruitingNCT05899608Phase 3
- AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05840016Phase 3
- AK112 in Advanced Non-Small Cell Lung CancerActive, not recruitingNCT05499390Phase 3
- A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT05432492Phase 2
- A Study of AK117/AK112 in Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05227664Phase 2
- Phase 3 Clinical Study of AK112 for NSCLC PatientsActive, not recruitingNCT05184712Phase 3
- Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLCCompletedNCT05116007Phase 1
- A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian CancerTerminatedNCT04999605Phase 1/2
- A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLCCompletedNCT04900363Phase 1/2
- Study of AK112 in the Treatment of Advanced Gynecological TumorsCompletedNCT04870177Phase 2
- A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCActive, not recruitingNCT04736823Phase 2
- A Study of AK112 for Advanced Solid TumorsCompletedNCT04597541Phase 1/2
- A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid TumorsCompletedNCT04047290Phase 1